Additional Licensed Patents Clause Samples

Additional Licensed Patents. The parties agree that the [**] PATENTS are “LICENSED PATENTS” under the Agreement (as amended by Amendment No. 1).
View SourceView Similar (3)
Additional Licensed Patents. The Parties shall review and negotiate in good faith a possible addition to Schedule A or B if a Licensee believes that a Patent of the Licensor not listed in the Schedule was used in a product or service in development, sold, or offered for sale, by the Licensee Permitted Business as of or during the twelve (12) months prior to the Disposition Date.
View SourceView Similar (2)
Additional Licensed Patents. Subject to Section I(2) herein, the parties agree that the AMENDMENT NO. 2 PATENTS are “LICENSED PATENTS” under the AGREEMENT (as amended by AMENDMENT NO. 2).
View SourceView Similar (2)
Additional Licensed Patents. MDNA will promptly notify LabCorp in writing of any patent rights other than those listed on Exhibit A that are owned, licensed, or otherwise controlled by MDNA in the Territory at any time during the Term that may be useful to LabCorp in performing or selling Licensed Services in the Field, including without limitation any patent rights covering any improvements or modifications made by MDNA to its Prostate Mitomic Test. All such patent rights will automatically be included within the definition of "Licensed Patents" and the license granted in Section 2.1 for purposes of this Agreement without additional charge to LabCorp and its Affiliates.
View Source
Additional Licensed Patents. The parties agree that the [**] PATENTS are “LICENSED PATENTS” under the Agreement (as amended by Amendment No. 1). Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.
View Source
Additional Licensed Patents. In the event that, during the Term of this Agreement, a Party becomes aware of any issued Patent (whether such Patent issued prior to or after the Effective Date) Controlled by Editas or by an Affiliate of Editas that was an Affiliate of Editas as of the Effective Date that (a) is not set forth on Exhibit B or Exhibit C, (b) was so Controlled as of the Effective Date and (c) Covers the development, use, manufacture or sale of a Base Editing Therapy in the Field in the Territory, such Party shall notify the other Party and upon Beam’s request, the Parties shall, subject to Editas’s consent (such consent not to be unreasonably withheld, delayed or conditioned) and the Parties’ reasonable agreement on the Family of Patents to which such issued Patent belongs, take all necessary actions to make such issued Patent a Licensed Patent or Optioned Patent hereunder as applicable, including amending Exhibit B or Exhibit C of this Agreement to include such issued Patent, including the appropriate Family in Exhibit B or Exhibit C in which such issued Patent should be listed, if applicable. If the Parties are unable to agree on the Family of Patents to which a Patent belongs as provided in the immediately preceding sentence within [**] days following Beam’s request to have such Patent be a Licensed Patent or Optioned Patent hereunder, then such matter shall be determined in accordance with Section 10.2. For the avoidance of doubt, in the event that a Patent is made an Optioned Patent in a Family for which the applicable Option has been exercised prior to the date that such Patent is listed in such Family, such Patent shall, upon being listed in such Family, automatically be deemed licensed hereunder with such Family without any obligation to make any additional Option Exercise Payment with respect to such Patent.
View Source
Additional Licensed Patents. MDNA will promptly notify _____ in writing of any patent rights other than those listed on Exhibit A that are owned, licensed, or otherwise controlled by MDNA in the Territory at any time during the Term that may be useful to _____ in performing or selling Licensed Services in the Field, including without limitation any patent rights covering any improvements or modifications made by MDNA to its Prostate Mitomic Test. All such patent rights will automatically be included within the definition of "Licensed Patents" and the license granted in Section 2.1 for purposes of this Agreement without additional charge to _____ and its Affiliates.
View Source
Additional Licensed Patents. For a period of one year (1) after the Effective Date, if either Party discovers a Premier-licensable patent or patent application, which was in existence as of the Effective Date, that it believes CustomerSoft infringes, then Premier shall provide a license to CustomerSoft under such patent or patent application to perform such act, upon terms and conditions no less favorable than the terms of the license for the Licensed Patents hereunder. As used herein, “Premier-licensable” means that Premier can grant a license as set forth herein without owing any consideration, or triggering or violating any other obligation, to any third party.
View Source
Additional Licensed Patents. RE may from time to time elect to file patent applications or obtain patents covering the Collaboration IP. To the extent that RE does so, the prosecution and maintenance of such patents and patent applications shall be handled by RE at RE’s sole expense. All patent applications filed and patents obtained by RE that claim the Collaboration IP shall be deemed “Licensed Patents” hereunder and licensed to Casella as provided in Section 2; provided that because the Collaboration IP relates to Engineered Feedstock, it shall be deemed Engineered Feedstock IP and treated accordingly once such Collaboration IP becomes the subject of a patent application or issued patent.
View Source

Related to Additional Licensed Patents

  • Licensed Patents Immune Design, at its expense, shall have the first right to file, prosecute and maintain all Licensed Patents for which Immune Design has any exclusive rights under this Agreement using patent counsel reasonably approved by IDRI, including conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extension relating thereto. Immune Design shall conduct such filing, prosecution and maintenance in good faith, taking into consideration IDRI’s retained rights hereunder, and consistent with reasonable business judgment, provide IDRI with all relevant or material documentation and proposed filing in the Territory so that IDRI may be concurrently and promptly informed of the continuing prosecution, and consult with IDRI with regards to Immune Design’s patent strategy with the Licensed Patents for which Immune Design has any exclusive rights under this Agreement. Licensed Patents in the name of IDRI shall remain in the name of IDRI. Immune Design shall use commercially reasonable efforts to ***, as applicable. To the extent such ***, Immune Design shall provide IDRI reasonable opportunity to review and comment on such prosecution efforts regarding such Licensed Patents in the Territory, and any IDRI comments will be reasonably considered in such prosecution efforts, and included to the extent affecting the IDRI Exclusive Field or IDRI Territory, as the case may be. If Immune Design determines in its sole discretion to abandon or not maintain any Licensed Patent for which Immune Design has any exclusive rights under this Agreement in the Territory, then Immune Design shall promptly provide IDRI with written notice of such determination at least sixty (60) days before any deadline for taking action to avoid abandonment and shall provide IDRI with the right, opportunity and reasonable assistance to prepare, file, prosecute and maintain such Licensed Patent in the applicable jurisdiction in IDRI’s sole discretion and at IDRI’s expense, provided that Immune Design shall provide such reasonable assistance at its own costs and expenses. If IDRI elects to prepare, file, prosecute and maintain such Licensed Patent in such jurisdiction for which Immune Design has any exclusive rights, then Immune Design’s license rights to such Licensed Patent in such country will become nonexclusive in such country under such Licensed Patent (and/or patent application). If IDRI desires Immune Design to file, in a particular jurisdiction, a Licensed Patent for which Immune Design has any exclusive rights under this Agreement that claims priority to another Licensed Patent for which Immune Design has any exclusive rights under this Agreement, IDRI shall provide written notice to Immune Design requesting that Immune Design file such patent application in such jurisdiction. If IDRI provides such written notice to Immune Design, Immune Design shall either (i) file and prosecute such patent application and maintain any patent issuing thereon in such jurisdiction and the Parties shall share the related costs and expenses (A) in countries *** on the basis of *** percent (***%) Immune Design: *** percent (***%) IDRI or (B) in countries within the IDRI Territory equally; or (ii) notify IDRI that Immune Design does not desire to file such patent application in such jurisdiction and provide IDRI with the opportunity to file and prosecute such patent application, provided that if IDRI files and prosecutes such patent application in such jurisdiction, then Immune Design’s license rights to such License Patent in such country will become nonexclusive in such country under such Licensed GLA Patent (and/or patent application). Immune Design shall be responsible for the costs and expenses incurred in connection with its own activities for filing, prosecuting and maintaining the Licensed Patents; IDRI shall be responsible for monitoring of such activities by IDRI.

  • Licensed Patent Rights The Licensee shall indemnify and hold the IC, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of:

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Joint Patent Rights If not already established under the Research Collaboration Agreement, prior to either Party filing any Patent Right disclosing Joint Program Technology or Joint Probody Platform Improvements, the Parties shall establish a patent committee (the “Patent Committee”) comprised of at least one (1) representative of each Party for the purpose of facilitating the preparation, filing, prosecution, maintenance and defense of Joint Patent Rights. As agreed upon by the Parties, meetings of the Patent Committee may be face-to-face or may be conducted by teleconferences or videoconferences, from time to time as needed. The Patent Committee will be the forum through which the Parties coordinate their respective obligations to each other described in Sections 5.2.2 and 5.2.3 hereof and in this Section. In the event the Parties conceive or generate any Joint Program Technology or Joint Probody Platform Improvements, the Parties shall promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon, which Party will control filing, prosecution and maintenance of such patents and how to pay for the filing, prosecution and maintenance of such patents. It is presumed that ImmunoGen will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint Program Technology or Joint Conjugation Probody Platform Improvements, and that CytomX will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint Unconjugated Probody Platform Improvements. Neither Party will file any Joint Patent Right without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. The Party controlling filing and prosecution of any such Joint Patent Right (a) shall keep the other Party informed regarding each Patent Right, (b) shall consider in good faith any recommendations made by the other Party in regard to the filing, prosecution or maintenance of any such Patent Right and (c) shall not unreasonably refuse to incorporate any recommendations made by the other Party in regard to such filing, prosecution or maintenance.

  • ROYALTIES AND PATENTS The Contractor shall pay all royalties and license fees. The Contractor shall defend all suits or claims for infringement of any patent rights and shall save the State harmless from loss on account thereof, except that the State shall be responsible for all such loss when a particular design, process or the product of a particular manufacturer or manufacturers is specified, but if the Contractor has reason to believe that the design, process or product specified is an infringement of a patent, The Contractor shall be responsible for such loss unless he promptly gives such information to the Architect.